Apr 17, 2017
Prima BioMed Receives Approval for Third Cohort of Phase I Melanoma Trial
Apr 11, 2017
Prima BioMed receives A$492,144 Tax Refund from Australian Government
Mar 15, 2017
Prima BioMed Completes Recruitment for Second Patient Cohort in Melanoma Trial and Will Present at ICI Conference in Boston
Mar 01, 2017
USA Patent Grants for IMP321 in Cancer
Feb 24, 2017
First Half 2017 Operational Update
Feb 13, 2017
Prima BioMed Receives ~A$860,000 Tax Credit Payment from French Government
Jan 23, 2017
Prima BioMed to Present at 2nd Annual Cancer Immunotherapy Conference
Jan 20, 2017
Prima BioMed Commences Randomised Phase IIb Clinical Trial for IMP321 in Breast Cancer
Jan 18, 2017
Prima BioMed to Maintain NASDAQ Listing
Jan 12, 2017
Prima BioMed Commences Recruitment for Second Cohort of Melanoma Trial
Jan 05, 2017
Prima BioMed enters new Material Transfer Agreement with Cytlimic
Jan 02, 2017
Prima announces new Product Candidate IMP761 – a LAG-3 Agonist Antibody
